Ovarian cancer
Ovarian cancer is a malignant neoplasm arising in the ovary, fallopian tube, or peritoneum, and the most lethal gynecologic Cancer in high-income countries; worldwide, cervical Cancer causes more deaths.
Ovarian cancer is a malignant neoplasm arising in the ovary, fallopian tube, or peritoneum, and the most lethal gynecologic Cancer in high-income countries; worldwide, cervical Cancer causes more deaths. High-grade serous carcinoma (HGSOC) accounts for most cases and the worst outcomes, and the evidence now indicates that it usually begins not in the ovary but in the fimbriated end of the fallopian tube, where serous tubal intraepithelial carcinoma lesions carrying the same TP53 mutation precede it. That reassignment of origin is why opportunistic salpingectomy has become a prevention strategy. Nearly all HGSOC carries a TP53 mutation; about a fifth involves germline or somatic BRCA1 or BRCA2 defects, and roughly half shows homologous recombination deficiency more broadly. Risk rises with the number of lifetime ovulatory cycles and with hereditary predisposition syndromes, and falls with pregnancy, breastfeeding, and combined oral contraceptive use.
The disease is often called a silent killer because its early symptoms — bloating, early satiety, pelvic discomfort — are nonspecific, so most diagnoses come after peritoneal dissemination. Screening does not change that: large randomized trials of CA-125 and ultrasound in the general population shifted stage at diagnosis without reducing Mortality, and CA-125 is therefore used for monitoring treated disease rather than for detection. Five-year survival remains near 30% for advanced HGSOC, against over 90% for disease confined to the ovary.
Standard first-line treatment combines cytoreductive surgery, with completeness of resection among the strongest prognostic factors, and platinum-based chemotherapy — carboplatin with paclitaxel — after which maintenance Therapy is chosen by molecular status: a PARP inhibitor such as olaparib for BRCA-mutated or homologous recombination–deficient Tumors, bevacizumab for others. Platinum resistance, defined by how soon disease returns after treatment, governs subsequent options and remains the central clinical problem; response rates fall and few later regimens are durable. Antibody-drug conjugates directed at Folate receptor alpha have entered practice for platinum-resistant disease, while checkpoint inhibitor Therapy has largely disappointed here — HGSOC is immunologically cold — and work continues on the tumor microenvironment that makes it so.
Where the papers sit
11 papers from the last 6 months study ovarian cancer directly · updated from PubMed 15 Nov 2026
Study type 0 clinical trials · 4 observational · 3 human data · 3 preclinical · 1 unclassified
Themes no clear themes · 1 new direction
Those 11 do not share a common subject.
-
The topics range from ovarian cancer diagnosis and treatment to gynecologic cancer services, immune-cell biology, and haemophilic arthropathy. They share biomedical and clinical investigation but no unifying disease, mechanism, or endpoint. Individual studies address cfDNA fragmentomics, serum biomarkers, molecular profiling, radionuclide therapy, platinum complexes, hydrogels, and healthcare impacts. No coherent research direction or common therapeutic trend emerges from the group.
Ovarian cancer becomes a culturally situated health-knowledge and research-priority problem
The Pacific women’s knowledge and perceptions study treats ovarian cancer not as a tumour to diagnose, profile, model, or treat, but as a subject of community-defined understanding, prevention, early detection, quality-of-life priorities, and culturally preferred care. It found poor recognition of ovarian-cancer symptoms and treatments, alongside interest in traditional healers and alternative practitioners, shifting the direction toward culturally co-designed communication and research priorities rather than another biomedical intervention or disease model 42462231Jul.
Papers
The 11 papers from the last 6 months that study ovarian cancer directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
No clear themes (11)
- Preoperative discrimination of malignant and benign ovarian masses using cfDNA fragmentomics and serum biomarkers. Molecular biomedicine · 9 Nov 2026 PMID 43002351
- Is the preoperative routine blood test workable to distinguish early-stage from advanced-stage ovarian cancer? Taiwanese journal of obstetrics & gynecology · 28 Oct 2026 PMID 42951464
- Molecular profiling of ovarian cancer is feasible and provides valuable therapeutic and research information to women in Aotearoa New Zealand. The New Zealand medical journal · 23 Oct 2026 PMID 42912973
- Impact of the COVID-19 pandemic on diagnosis, treatment, and prognosis of cervical, endometrial, and ovarian cancers: A retrospective cohort study based on the SEER database. Medicine · 17 Oct 2026 PMID 42888541
- A 177Lu-Labeled Circular Bivalent Aptamer for PTK7-Targeting Radionuclide Therapy in Ovarian Cancer and Orthotopic Hepatoblastoma. Journal of medicinal chemistry · 10 Sept 2026 PMID 42720498
- Expanding the scope of platinum-NHC complexes: trans-Pt(II) and Pt(0) architectures for ovarian cancer treatment. Dalton transactions (Cambridge, England : 2003) · 20 Aug 2026 PMID 42622541
- Knowledge and perceptions of gynaecological cancers of Pacific women in Aotearoa New Zealand. The New Zealand medical journal · 16 Jul 2026 PMID 42462231
- Syringeable hyaluronic acid-based hydrogel co-loaded with cisplatin and MSA-2 for enhanced ovarian cancer chemoimmunotherapy. Biomedical materials (Bristol, England) · 15 Jul 2026 PMID 42456758
- Clonal lineage tracing of innate immune cells in human cancer. Cancer cell · 4 Jun 2026 PMID 42242233
- Multi-omics and pan-cancer analysis revealed common molecular signatures to disclose multitargeted anticancer agents through network pharmacology approach. PloS one · 1 Jun 2026 PMID 42224282
- The biomarkers uCTX-II, CS846 and IGF-1 are associated with clinical and ultrasound scores in haemophilic arthropathy: a cross-sectional study. Rheumatology international · 30 May 2026 PMID 42217051
By study type
Observational studies and case reports (4)
- Is the preoperative routine blood test workable to distinguish early-stage from advanced-stage ovarian cancer? Taiwanese journal of obstetrics & gynecology · 28 Oct 2026 PMID 42951464
- Impact of the COVID-19 pandemic on diagnosis, treatment, and prognosis of cervical, endometrial, and ovarian cancers: A retrospective cohort study based on the SEER database. Medicine · 17 Oct 2026 PMID 42888541
- Knowledge and perceptions of gynaecological cancers of Pacific women in Aotearoa New Zealand. The New Zealand medical journal · 16 Jul 2026 PMID 42462231
- The biomarkers uCTX-II, CS846 and IGF-1 are associated with clinical and ultrasound scores in haemophilic arthropathy: a cross-sectional study. Rheumatology international · 30 May 2026 PMID 42217051
Human data, design not indexed (3)
- Preoperative discrimination of malignant and benign ovarian masses using cfDNA fragmentomics and serum biomarkers. Molecular biomedicine · 9 Nov 2026 PMID 43002351
- Molecular profiling of ovarian cancer is feasible and provides valuable therapeutic and research information to women in Aotearoa New Zealand. The New Zealand medical journal · 23 Oct 2026 PMID 42912973
- Multi-omics and pan-cancer analysis revealed common molecular signatures to disclose multitargeted anticancer agents through network pharmacology approach. PloS one · 1 Jun 2026 PMID 42224282
Preclinical: animal, cell and lab studies (3)
- A 177Lu-Labeled Circular Bivalent Aptamer for PTK7-Targeting Radionuclide Therapy in Ovarian Cancer and Orthotopic Hepatoblastoma. Journal of medicinal chemistry · 10 Sept 2026 PMID 42720498
- Expanding the scope of platinum-NHC complexes: trans-Pt(II) and Pt(0) architectures for ovarian cancer treatment. Dalton transactions (Cambridge, England : 2003) · 20 Aug 2026 PMID 42622541
- Syringeable hyaluronic acid-based hydrogel co-loaded with cisplatin and MSA-2 for enhanced ovarian cancer chemoimmunotherapy. Biomedical materials (Bristol, England) · 15 Jul 2026 PMID 42456758
Unclassified: not yet indexed with MeSH (1)
- Clonal lineage tracing of innate immune cells in human cancer. Cancer cell · 4 Jun 2026 PMID 42242233
Written from 11 PubMed abstracts, each one listed by PMID above. Published: 2026-06-16. Last written: 2026-09-12 by GPT. Corrections: 2026-08-08 by GPT. Drafted by language models from published abstracts; not medical advice.